Mankind Pharma IPO description – Mankind Pharma is India’s fourth-largest pharmaceutical company in terms of domestic sales and second-largest in terms of sales volume in FY 2022. The company is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.
The company is focused on the domestic market which contributed 97.6% of its total revenue from operations for FY 2022. Mankind Pharma has created 36 brands in its pharmaceutical business that have each achieved over INR 50 crore in domestic sales in FY 2022. The company is present in several acute and chronic therapeutic areas in India, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory.
As of 31 March 2022, Mankind Pharma operated 23 manufacturing facilities across India and had 2,181 manufacturing personnel. Its formulations manufacturing facilities have a total installed capacity of 40.77 billion units across a wide range of dosage forms including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives, other over-the-counter products. The company had a team of over 600 scientists and dedicated in-house R&D center at IMT Manesar, Haryana.
Promoters of Mankind Pharma – Ramesh Juneja, Rajeev Juneja, Sheetal Arora, Ramesh Juneja Family Trust, Rajeev Juneja
Mankind Pharma IPO Details
| Mankind Pharma IPO Dates | 25 – 27 April 2023 |
| Mankind Pharma IPO Price | INR 1,026 – 1,080 per share |
| Fresh issue | Nil |
| Offer For Sale | 4,00,58,844 shares (INR 4,110.04 – 4,326.36 crore) |
| Total IPO size | INR 4,326.36 crore |
| Minimum bid (lot size) | 13 shares (INR 14,040) |
| Face Value | INR 1 per share |
| Retail Allocation | 35% |
| Listing On | BSE, NSE |
Mankind Pharma Financial Performance
| Â | FY 2020 | FY 2021 | FY 2022 | 9M FY 2023 |
| Revenue | 5,865.2 | 6,214.4 | 7,781.6 | 6,696.8 |
| Expenses | 4,549.5 | 4,705.5 | 6,017.4 | 5,493.5 |
| Net income | 1,056.2 | 1,293.0 | 1,453.0 | 1,010.2 |
| PAT Margin (%) | 18.0 | 20.8 | 18.7 | 15.1 |
Mankind Pharma Offer News
- Mankind Pharma RHP
- Mankind Pharma Draft Prospectus
- ASBA IPO Forms
- Live IPO Subscription Status
- IPO Allotment Status
Mankind Pharma Valuations & Margins
| FY 2020 | FY 2021 | FY 2022 | |
| EPS | 25.72 | 31.59 | 35.78 |
| PE ratio | – | – | 28.68 – 30.18 |
| RONW (%) | 29.56 | 26.80 | 23.29 |
| NAV | – | – | 153.65 |
| ROCE (%) | 35.86 | 30.41 | 25.50 |
| EBITDA (%) | 24.69 | 26.71 | 25.75 |
| Debt/Equity | (0.03) | 0.02 | 0.08 |
Mankind Pharma IPO GMP Today
| Date | Consolidated IPO GMP | Kostak | Subject to Sauda |
| 8 May 2023 | 90 | 850 | – |
| 6 May 2023 | 85 | 700 | – |
| 5 May 2023 | 85 | 600 | – |
| 4 May 2023 | 80 | 600 | 800 |
| 3 May 2023 | 70 | 500 | 600 |
| 2 May 2023 | 75 | 500 | 650 |
| 29 Apr 2023 | 70 | 500 | 600 |
| 28 Apr 2023 | 55 | 450 | 550 |
| 27 Apr 2023 | 45 | 400 | 500 |
| 26 Apr 2023 | 70 | 550 | 600 |
| 25 Apr 2023 | 85 | 650 | 750 |
| 24 Apr 2023 | 75 | 500 | 700 |
| 21 Apr 2023 | 80 | 500 | 750 |
| 20 Apr 2023 | 80 | 500 | 750 |
| 19 Apr 2023 | 90 | 550 | 800 |
| 18 Apr 2023 | 80 | 500 | 700 |
| 17 Apr 2023 | 90 | 550 | 800 |
| 15 Apr 2023 | 100 | 600 | 850 |
Mankind Pharma IPO Subscription – Live Updates
| Category | QIB | NII | Retail | Total |
| Shares Offered | 80,11,769 | 60,08,827 | 1,40,20,596 | 2,80,41,192 |
| 27 Apr 2023 | 49.16 | 3.80 | 0.92 | 15.32 |
| 26 Apr 2023 | 1.86 | 1.02 | 0.25 | 0.87 |
| 25 Apr 2023 | 0.07 | 0.33 | 0.11 | 0.14 |
Mankind Pharma IPO Reviews – Subscribe or Avoid?
Aditya Birla Capital – Subscribe
Angel One –
Anand Rathi –
Antique Stock Broking –
Arihant Capital –
Ashika Research – Compelling Investment Opportunity
Asit C Mehta – Subscribe
BP Wealth – Avoid
Canara Bank Securities – Subscribe
Centrum Broking – Subscribe
Choice Broking – Subscribe
Dalal & Broacha –
Elite Wealth – Subscribe for Long-Term
Geojit – Subscribe
GEPL Capital – Subscribe
Hem Securities – Long-Term Subscribe
ICICIdirect – Subscribe
Jainam Broking –
KR Choksey –
LKP Research –
Marwadi Financial – Subscribe
Motilal Oswal –
Nirmal Bang –
Reliance Securities –
Religare Broking –
Samco Securities – Avoid
SBI Capital – Subscribe
SMC Global – 2/5
Swastika Investmart – Subscribe
Ventura Securities –
Mankind Pharma Offer Registrar
KFIN TECHNOLOGIES LIMITED
Selenium Tower – B, Plot 31 & 32, Gachibowli,
Financial District, Nanakramguda, Serilingampally,
Hyderabad – 500 032, Telangana
Telephone: +91 40 6716 2222
Email: [email protected]
Website:Â www.kfintech.com
Mankind Pharma Contact Details
MANKIND PHARMA LIMITED
262, Okhla Industrial Estate, Phase-III,
New Delhi 110 020, Delhi, India
Phone: +91 11 4684 6729
E-mail: [email protected]
Website: www.mankindpharma.com
Mankind Pharma IPO Allotment Status
Mankind Pharma IPO allotment status is now available on the KFin Tech website. Click on this link to get allotment status.
Mankind Pharma IPO Dates & Listing Performance
| Mankind Pharma IPO Opening Date | 25 April 2023 |
| Mankind Pharma IPO Closing Date | 27 April 2023 |
| Finalization of Basis of Allotment | 3 May 2023 |
| Initiation of refunds | 4 May 2023 |
| Transfer of shares to demat accounts | 8 May 2023 |
| Mankind Pharma Listing Date | 9 May 2023 |
| Opening Price on NSE SME | INR 1,300 per share (up 20.37%) |
| Closing Price on NSE SME | INR 1,422.3 per share (up 31.7%) |
Read Also: Nifty Pharma Stocks List With Weightage in 2023
Mankind Pharma IPO FAQs
How many shares in Mankind Pharma IPO are reserved for HNIs and retail investors?
The investors’ portion for QIB – 50%, NII – 15%, and Retail – 35%.
How to apply for Mankind Pharma Public Offer?
The best way to apply for Mankind Pharma public offer is through Internet banking ASBA (know all about ASBA here). You can also apply online through your stock broker using UPI. If you prefer to make paper applications, fill up an offline IPO form and deposit the same to your broker.
What is Mankind Pharma IPO GMP today?
Mankind Pharma IPO GMP today is INR 90 per share.
What is Mankind Pharma’s kostak rate today?
Mankind Pharma kostak rate today is INR 850 per application.
What is Mankind Pharma Subject to Sauda rate today?
Mankind Pharma Subject to Sauda rate today is NA per application.
Premium around 105 so 10% premium is not a big deal. It might even go down after IPO is closed.
As expected, it is going down now after ipo timetable is confirmed.
IPO is overpriced and sentiments are not good currently. GMP is declining due various reasons so not good time for investment. Who knows what will be premium at the time of listing it could be negative too.